Home » Stocks » GENE

Genetic Technologies Ltd. (GENE)

Stock Price: $4.30 USD -0.07 (-1.60%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
After-hours: $4.40 +0.10 (2.33%) Jan 20, 7:57 PM
Market Cap 67.32M
Revenue (ttm) 6,803
Net Income (ttm) -4.21M
Shares Out 4.16B
EPS (ttm) -0.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $4.30
Previous Close $4.37
Change ($) -0.07
Change (%) -1.60%
Day's Open 4.37
Day's Range 4.25 - 4.59
Day's Volume 476,354
52-Week Range 1.45 - 5.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

MELBOURNE, Australia, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce an interview with ...

GlobeNewsWire - 2 months ago

MELBOURNE, Australia, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce its interim-CEO, D...

GlobeNewsWire - 3 months ago

MELBOURNE, Australia, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market ...

GlobeNewsWire - 4 months ago

MELBOURNE, Australia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG, NASDAQ:GENE) (“Genetic Technologies” or the "Company") is devel...

GlobeNewsWire - 4 months ago

MELBOURNE, Australia, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”) is delighted to announce that initial sale...

GlobeNewsWire - 4 months ago

MELBOURNE, Australia, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, ...

GlobeNewsWire - 6 months ago

MELBOURNE, Australia, July 20, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, t...

Zacks Investment Research - 6 months ago

Vaccine hopes and some upbeat banking earnings have boosted the risk-on sentiments in Wall Street.

Other stocks mentioned: JETS, KRE, MORT, PEJ, PSCH, RCL
GlobeNewsWire - 6 months ago

MELBOURNE, Australia, July 16, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, t...

GlobeNewsWire - 6 months ago

Highlights

GlobeNewsWire - 6 months ago

MELBOURNE, Australia, June 23, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) is pleased to announce that its in...

GlobeNewsWire - 7 months ago

MELBOURNE, Australia, May 28, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, to...

GlobeNewsWire - 7 months ago

MELBOURNE, Australia, May 26, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, to...

GlobeNewsWire - 7 months ago

MELBOURNE, Australia, May 22, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) provides the following operational updates:

GlobeNewsWire - 8 months ago

MELBOURNE, Australia, May 20, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is to commence accelerating development of a polygenic risk score (PRS) test to p...

GlobeNewsWire - 9 months ago

Temporary transition to high throughput COVID-19 testing Temporary transition to high throughput COVID-19 testing

GlobeNewsWire - 9 months ago

MELBOURNE, Australia, April 06, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, ...

InvestorPlace - 9 months ago

Genetic Tech (GENE) news for Wednesday includes GENE stock falling after the release of consumer tests for breast and colorectal cancer.

GlobeNewsWire - 9 months ago

MELBOURNE, Australia, April 01, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, ...

GlobeNewsWire - 9 months ago

MELBOURNE, Australia, April 01, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the ...

GlobeNewsWire - 10 months ago

MELBOURNE, Australia, March 13, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a  leader in the development of genetic risk assessment tests,...

GlobeNewsWire - 1 year ago

MELBOURNE, Australia, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE) is pleased to advise that its third-generation bre...

GlobeNewsWire - 1 year ago

MELBOURNE, Australia, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce the full commissioning of its Australian Labor...

GlobeNewsWire - 1 year ago

MELBOURNE, Australia, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company, announced today an upda...

Benzinga - 1 year ago

Genetic Technologies Limited (NYSE: GENE), a provider of world-leading genetic risk assessment test products today announced that it has signed a 3-year Collaboration Agreement with TGen.

About GENE

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the comp... [Read more...]

Industry
Diagnostics & Research
Founded
1989
CEO
Dr. Jerzy Muchnicki MBBS
Stock Exchange
NASDAQ
Ticker Symbol
GENE
Full Company Profile

Financial Performance

In 2020, GENE's revenue was 9,864, a decrease of -61.23% compared to the previous year's 25,444. Losses were -6.10 million, -5.08% less than in 2019.

Financial numbers in millions AUD.
Financial Statements